(January 30, 2014) OCRF grantee Yin Wang, PhD, led research which found that PKC iota signaling plays an important role in ovarian cancer development. The research, which was published in Molecular Cancer Research, also found that Auranofin, a small molecular compound, shows potential for treating ovarian cancer. The research study was funded in part by … Continued
At least 20% of women with ovarian cancer have a genetic predisposition to the disease even if they don’t have a family history ovarian cancer, according to a recent study. Researchers at Washington University School of Medicine in St. Louis analyzed the genes in ovarian cancer tumor samples from over 400 women with no family … Continued
(January 22, 2014) Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute, the Centers for Disease Control … Continued
(January 13, 2014) Researchers at Case Western Reserve University, led by OCRFA grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a finding that has the potential to improve outcomes for patients with the disease. The findings were published … Continued
Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, Ovarian Cancer Research Fund has awarded a record-breaking $6.9 million in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. … Continued
OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country.
A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, researchers took advantage of the fact that ovarian cancer cells have abnormally high a marker called NY-ESO-1 on their surfaces. Researchers gave patients a drug … Continued
New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued
(December 30, 2013) The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of a BRCA-related cancer (cancer of the breast, ovary, fallopian tube, or … Continued
(December 20, 2013) Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival. The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian cancer, the provider combination of high volume hospital/high volume provider is an … Continued
A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable. The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer. Read the full article here.
Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued
Get email updates about research news, action alerts, and ways to join the fight.
